创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

HU Yuhan, YU Wanting, XIONG Jing. Oncogene-driven Metabolic Reprogramming in Liver Cancer and Potential Therapeutic Strategies[J]. Progress in Pharmaceutical Sciences, 2025, 49(7): 524-534. DOI: 10.20053/j.issn1001-5094.20250025
Citation: HU Yuhan, YU Wanting, XIONG Jing. Oncogene-driven Metabolic Reprogramming in Liver Cancer and Potential Therapeutic Strategies[J]. Progress in Pharmaceutical Sciences, 2025, 49(7): 524-534. DOI: 10.20053/j.issn1001-5094.20250025

Oncogene-driven Metabolic Reprogramming in Liver Cancer and Potential Therapeutic Strategies

  • Liver cancer is a common and deadly malignant tumor worldwide, and the abnormalities of oncogenes play a pivotal role in its initiation and progression. In-depth exploration of the oncogene-mediated metabolic mechanisms in liver cancer is expected to open up new avenues for the precision treatment, thereby promoting the diagnosis and treatment improvement of the disease. This article introduces the abnormal conditions of oncogenes in liver cancer and clarifies how these abnormalities drive the reprogramming of liver cancer metabolic pathways through transcriptional regulation, post-translational modification, and other mechanisms, thereby supporting the proliferation and survival needs of tumor cells. Furthermore, the feasibility of combining existed liver cancer treatment with drugs targeting oncogeneinduced metabolic remodeling in liver cancer is discussed, aiming to provide ideas and references for optimizing the combined treatment plan of liver cancer, overcoming tumor drug resistance, improving the prognosis, and prolonging survival.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return